Xellia Pharmaceuticals

About Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company and a global leader in providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions. Xellia has an extensive heritage in developing, manufacturing, and commercializing anti-infective products. Headquartered in Copenhagen, Denmark, and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1100 employees globally, including state-of-the-art manufacturing sites in China, Denmark, and Hungary. Our strong market position is built on more than 120 years of pharmaceutical industry experience.